|
|
Post by vissertrades on Oct 8, 2015 19:09:19 GMT -5
Matt told me about "short the launch" typical in biotech so management new price would fall especially with slooooow, handcuffed, and meager dtc launch. Who's best interest is this in, stockholders? Seems real fishy.
|
|
|
|
Post by patryn on Oct 8, 2015 19:54:15 GMT -5
If you have been in the stock more than a year, then the lack of transparency should have already been apparent before today. The management of MNKD is focused on creating long term value in MNKD which should ultimately reward shareholders, but could be to the detriment of those who demand constant updates as to progress.
The truth is that the marketing and sales has been outsourced by MNKD to SNY and SNY is doing what it wants to in regards to that. I'm sure none of the shareholders of MNKD wanted the sales to be tepid at the moment, but SNY definitely has it's hands on the switch and there is nothing that MNKD management can do about it short of attempting to break the contract signed less than a year ago. We as shareholders of MNKD signed up for this arrangement because we knew the alternative was trying to market and sell Afrezza by ourselves which would have required far more capital outlay and expertise that no one at MNKD had.
Matt could have given the best presentation in the world, and electrified the audience with his wit, vivacity, and charm. It would not change the sales picture one bit. Afrezza adoption needs to come from a well orchestrated marketing, education, and sales campaign and that is something that will take time.
I have invested more than 10x what you have in MNKD and while I do not like the short term, I am content with my investment because I know that the odds of success are better than the odds of failure, and I know that there is a floor price at which the component pieces of MNKD can be offered to the highest bidder so my risk/reward ratio is good. I will continue to evaluate this over time with the only metric that matters - Cash flow - Sales versus Expenses. As long as MNKD can keep the doors open and the script growth continues, then the risk/reward ratio does not alter for me. Everything else including random presentations to investment banks is just noise.
|
|
|
|
Post by jimo on Oct 8, 2015 20:53:14 GMT -5
It'S NOT funny. I feel your pain as I have more invested and for much longer. Dysfunctional situation with current management and a billionare owner that is set. Hoping we get there is not good enough, we need measureable milestones and a plan to achieve those goals. Current secrecy has to stop as I feel they can't share what they don't have and that's a problem - BOD should act. Probably not a popular sentiment, but I believe that the legal contract with SNY prevents Mnkd mgmt from saying anything. Further as historically this leads to a drop in the target company stock, it is even more strongly enforced especially during a slower launch. Forward strat plan for some big pharma is to slow roll and use social media and trim there holdings over time versus paying the huge bucks up front. You're right on with view bio, I enjoy reading your reality based posts. SNY runs sales and marketing for Afrezza so Matt & team can't say anything but "we're happy with our partner". This is all MNKD can say even though they're months behind their sales plan and watched their stock go from 10 to 3 in a year. MNKD has to be super frustrated with SNY but can't do a thing about their approach. I'm learning a lot of hard lessons on this one like when you give control to a 3rd party all bets are off. |
|
|
|
Post by mnholdem on Oct 8, 2015 21:38:48 GMT -5
]One question i often wonder is when Al invented the insulin pump and it was made available to patients, was it similar to this? Did insurance companies, Doctors, etc. adopt it quickly or did it take time for everyone to become educated on it, finding out about it, adopting it, etc.? If my memory serves me right I believe Minimed SP was driven down to sub $2's before Medtronic BO , no idea re: insurance adoption but since it was a new technology I'd imagine they had similar hurdles to overcome . Just my 02 cents  Lynn Sales started out slow, from $40 million in sales in 1994 to nearly $400 million anticipated sales in 2001 when it was sold. Shares of MiniMed rose $2.77 to $46.77 on news of the sale.
|
|
|
|
Post by compound26 on Oct 8, 2015 23:11:32 GMT -5
If my memory serves me right I believe Minimed SP was driven down to sub $2's before Medtronic BO , no idea re: insurance adoption but since it was a new technology I'd imagine they had similar hurdles to overcome . Just my 02 cents Lynn Sales started out slow, from $40 million in sales in 1994 to nearly $400 million anticipated sales in 2001 when it was sold. Shares of MiniMed rose $2.77 to $46.77 on news of the sale.
Medtronic to Buy MiniMed and AffiliateDeals: The No. 1 medical device maker agreed to pay $3.28 billion for the diabetes management concern in buying spree. May 31, 2001|KAREN ROBINSON-JACOBS | TIMES STAFF WRITER Moving its aggressive acquisition campaign into the field of diabetes management, Medtronic Inc., the world's biggest medical device maker, agreed to buy Northridge-based MiniMed Inc. and an affiliated company for $3.7 billion, the companies said Wednesday. As part of the deal, MiniMed's founder, Alfred E. Mann, will step down as chairman and chief executive to devote attention to his other medical start-ups. If approved by shareholders and regulators, the $3.28 billion cash purchase of MiniMed would be the third $3 billion-plus acquisition by Minneapolis-based Medtronic in three years. In addition to MiniMed, a leader in the development and sale of diabetes management devices including insulin pumps, Medtronic agreed to purchase Mann's closely held Medical Research Group Inc. for $420 million in cash and stock. Medtronic said it will pay $48 a share for MiniMed, a 9.1% premium over Tuesday's closing stock price, but a near doubling of the $25-per-share price seen in April, before rumors of a MiniMed sale began circulating.
Shares of MiniMed rose $2.77 to $46.77 Wednesday on Nasdaq on news of the sale. Medtronic, which has a $51 billion market capitalization and is known largely for its cardiac and neurological product lines, gained a nickel to close at $43 on the Big Board. MiniMed will remain at its new Northridge headquarters and no layoffs are planned, according to Medtronic President and Chief Executive Art Collins. Company officials and analysts said the deal, hammered out in round-the-clock sessions that ended at 4 a.m. Wednesday, gives both companies a shot in the arm. For MiniMed, which has grown from $40 million in sales in 1994 to nearly $400 million anticipated for this year, Medtronic offers marketing muscle and distribution possibilities in the 120 countries where Medtronic is an established presence. It also opens the possibility for use of MiniMed's pumps to treat illness other than diabetes. And it offers a friendly harbor for a company that's seen its share price drop from nearly $93 last September. For Medtronic, MiniMed offers a beachhead into the field of technological management of diabetes, one of the fastest-growing chronic diseases in the country and one that affects an estimated 16 million Americans. The devices produced by MiniMed help patients manage their insulin needs and monitor glucose levels. "It makes sense for both sides," said Ryan Rauch, senior analyst on the medical device team of Adams, Harkness & Hill. MiniMed, he said, is facing increasing competition in its franchise external insulin pump business. And he said there were questions about when the consumer version of the company's continuous glucose monitor will be ready for scrutiny by the Food and Drug Administration and ultimately for the marketplace. At $3.28 billion, the price is more than 14 times 2000 sales, Rauch said, noting that the average for medical device companies has been about six to eight times sales. On the other hand, he said, Medtronic reported stagnant sales for its cardio-defibrillator implants, a core product line. "What Medtronic bought was top-line growth," Rauch said. "Now they're in the fast-moving, $3 billion to $5 billion diabetes marketplace. And MiniMed offers them the best diabetes franchise." |
|
|
|
Post by rockstarrick on Oct 8, 2015 23:33:41 GMT -5
I'm long on this stock and have been in for more than a year with about $150,000 originally invested. Some of the popular complaints are: Lack of Nrx; Lack of commercials/impotent DTC campaign; Insurance companies not yet on board; Not enough doctors are educated sufficiently about Afrezza (if they have even heard of it at all). The stock price is embarrassing. The very standard and tiring response to each one of these is that SNY knows what it is doing and the rollout is a very precisely controlled rollout and is even supported by documents purportedly put out by SNY showing how they plan to be precise and do the rollout over the long term. Today Matt, yet again, used such unnecessary language as (paraphrased) "unfortunately, we are not at the numbers we would like to see at this time." He keeps saying this and it is so damning to the company that I get very angry when I hear it (every conf call). Here is the rub: If SNY indeed is doing a precise rollout as it is being represented to all of us, then Matt's statements that he wished we were at higher numbers shows to me that either MNKD or SNY or both are behind the ball and things are not going as they expected them to go. Matt should he saying, taking all available info into account, that we are right on track and that as time goes by and SNY engages new elements of its rollout, things will continue to gain traction and sales will increase, etc etc. I am thoroughly dissatisfied with the progress, and cannot be anything other than dissatisfied because even Matt believes (or wishes) we should be further along. What is the real story? What is SNY's plan? Damn it, I want to know what the plan is. There is virtually no reason shareholders should not be given basic information about the plan (I don't mean statements like "we expect some TV ads by the end of 2015). I want to know what the basic plan is, and I want to hear a progress report. I wrote Matt an email this week which he quickly answered. I asked specific questions and he simply said he would try to answer some of the questions during today's conference. He said nothing of any investor value and nothing to suggest anything is improving. I just don't know if I believe what is in front of me or what everyone says is happening behind the lines... Matt certainly isn't supporting any position that the behind-the-lines actions are well calculated. Again, I walk away scratching my head. Well I didn't listen to the webcast today but I will say this. Afrezza and inhaled insulin is a completely new approach in the treatment of Diabetes, this radical change isn't going to happen overnight. With a pretty solid Chemistry background, I can tell you that Afrezza isn't going to just quit working, it will keep dropping A1c's with less risk of hypoglycemia, and in my opinion, will be a household name eventually. This little company isn't getting all this attention because people actually think it will fail, the attention is because these attention givers know Afrezza will succeed. Nothing will change.....Afrezza will continue to work great and afrezzausers will continue to live life as normal people. it will just take a little more time to get to our ultimate goal. My DD is rock solid and this long term investment is on cruise control, not a worry in the world. Great job Al Mann and Mannkind for getting us to this point, the silence doesn't bother me in the least. Afrezza is here to stay, in 5 years, in my opinion,you won't believe we were ever at $3/share. Oh, if you scratch your head too much it will give you a bald spot. Also, when you show your frustration, you are making the shorts day, this is the goal of every short, don't give that to them, try to find something good to focus on,(like how Afrezza is changing lives) and post with confidence. We will be fine when the time comes, when is the big question. Until then, bashing mnkd management is showing weakness and definitely could discourage any new buyers. Good Luck to you and all MNKD Longs.  ?? |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 8, 2015 23:44:25 GMT -5
I'm long on this stock and have been in for more than a year with about $150,000 originally invested. Some of the popular complaints are: Lack of Nrx; Lack of commercials/impotent DTC campaign; Insurance companies not yet on board; Not enough doctors are educated sufficiently about Afrezza (if they have even heard of it at all). The stock price is embarrassing. The very standard and tiring response to each one of these is that SNY knows what it is doing and the rollout is a very precisely controlled rollout and is even supported by documents purportedly put out by SNY showing how they plan to be precise and do the rollout over the long term. Today Matt, yet again, used such unnecessary language as (paraphrased) "unfortunately, we are not at the numbers we would like to see at this time." He keeps saying this and it is so damning to the company that I get very angry when I hear it (every conf call). Here is the rub: If SNY indeed is doing a precise rollout as it is being represented to all of us, then Matt's statements that he wished we were at higher numbers shows to me that either MNKD or SNY or both are behind the ball and things are not going as they expected them to go. Matt should he saying, taking all available info into account, that we are right on track and that as time goes by and SNY engages new elements of its rollout, things will continue to gain traction and sales will increase, etc etc. I am thoroughly dissatisfied with the progress, and cannot be anything other than dissatisfied because even Matt believes (or wishes) we should be further along. What is the real story? What is SNY's plan? Damn it, I want to know what the plan is. There is virtually no reason shareholders should not be given basic information about the plan (I don't mean statements like "we expect some TV ads by the end of 2015). I want to know what the basic plan is, and I want to hear a progress report. I wrote Matt an email this week which he quickly answered. I asked specific questions and he simply said he would try to answer some of the questions during today's conference. He said nothing of any investor value and nothing to suggest anything is improving. I just don't know if I believe what is in front of me or what everyone says is happening behind the lines... Matt certainly isn't supporting any position that the behind-the-lines actions are well calculated. Again, I walk away scratching my head. Well I didn't listen to the webcast today but I will say this. Afrezza and inhaled insulin is a completely new approach in the treatment of Diabetes, this radical change isn't going to happen overnight. With a pretty solid Chemistry background, I can tell you that Afrezza isn't going to just quit working, it will keep dropping A1c's with less risk of hypoglycemia, and in my opinion, will be a household name eventually. This little company isn't getting all this attention because people actually think it will fail, the attention is because these attention givers know Afrezza will succeed. Nothing will change.....Afrezza will continue to work great and afrezzausers will continue to live life as normal people. it will just take a little more time to get to our ultimate goal. My DD is rock solid and this long term investment is on cruise control, not a worry in the world. Great job Al Mann and Mannkind for getting us to this point, the silence doesn't bother me in the least. Afrezza is here to stay, in 5 years, in my opinion,you won't believe we were ever at $3/share. Oh, if you scratch your head too much it will give you a bald spot. Also, when you show your frustration, you are making the shorts day, this is the goal of every short, don't give that to them, try to find something good to focus on,(like how Afrezza is changing lives) and post with confidence. We will be fine when the time comes, when is the big question. Until then, bashing mnkd management is showing weakness and definitely could discourage any new buyers. Good Luck to you and all MNKD Longs. ?? Right on Rick. BTW...Chemistry background = pharmacist? |
|
|
|
Post by rockstarrick on Oct 9, 2015 0:32:31 GMT -5
If you have been in the stock more than a year, then the lack of transparency should have already been apparent before today. The management of MNKD is focused on creating long term value in MNKD which should ultimately reward shareholders, but could be to the detriment of those who demand constant updates as to progress. The truth is that the marketing and sales has been outsourced by MNKD to SNY and SNY is doing what it wants to in regards to that. I'm sure none of the shareholders of MNKD wanted the sales to be tepid at the moment, but SNY definitely has it's hands on the switch and there is nothing that MNKD management can do about it short of attempting to break the contract signed less than a year ago. We as shareholders of MNKD signed up for this arrangement because we knew the alternative was trying to market and sell Afrezza by ourselves which would have required far more capital outlay and expertise that no one at MNKD had. Matt could have given the best presentation in the world, and electrified the audience with his wit, vivacity, and charm. It would not change the sales picture one bit. Afrezza adoption needs to come from a well orchestrated marketing, education, and sales campaign and that is something that will take time. I have invested more than 10x what you have in MNKD and while I do not like the short term, I am content with my investment because I know that the odds of success are better than the odds of failure, and I know that there is a floor price at which the component pieces of MNKD can be offered to the highest bidder so my risk/reward ratio is good. I will continue to evaluate this over time with the only metric that matters - Cash flow - Sales versus Expenses. As long as MNKD can keep the doors open and the script growth continues, then the risk/reward ratio does not alter for me. Everything else including random presentations to investment banks is just noise. Couldn't agree more. If you are long MNKD, then you should expect at least 2 to 5 years after "launch" to see the gains we are hoping to see. Also, if you are a true long, and you are posting negative comments about MNKD and management on a public forum, you are hurting yourself and helping the shorts. In my opinion, it's ok to have bad MNKD days, but don't post your frustrations on a public forum, people read these forums just to see the moral of long investors, if there is post after post of longs bashing management, suggesting people get fired, do you think they'll buy, I don't. Im very proud of Al and Mannkind Management for all they've accomplished just getting approval, a partnership, and successfully launched Afrezza. Like I said, Afrezza is, and will continue, to change the lives of the Diabetics currently using it. Lets get behind Mannkind Management, let's show them we appreciate their hard work, and let's show some confidence in this investment. Very proud of the entire Mannkind Management team, not a pumper, just very confident. Good Luck to All MNKD Longs |
|
|
|
Post by LongMNKD on Oct 9, 2015 1:19:16 GMT -5
That's the frustrating part of this investment. Clearly an innovative treatment for millions of diabetics yet we have sales numbers of 500 after 8 months. Al, MNKD & SNY should be screaming about this product that will help save limbs & life! All we get is another presentation to hang in there..... frustrating ! But they are not allowed to because of FDA regulations and product label. The label improvements will help SO much. That's why Matt said they often tell news agencies to contact the patients themselves, because they can say things management is not allowed to say. |
|
|
|
Post by parrerob on Oct 9, 2015 3:29:40 GMT -5
It'S NOT funny. I feel your pain as I have more invested and for much longer. Dysfunctional situation with current management and a billionare owner that is set. Hoping we get there is not good enough, we need measureable milestones and a plan to achieve those goals. Current secrecy has to stop as I feel they can't share what they don't have and that's a problem - BOD should act. Probably not a popular sentiment, but I believe that the legal contract with SNY prevents Mnkd mgmt from saying anything. Further as historically this leads to a drop in the target company stock, it is even more strongly enforced especially during a slower launch. Forward strat plan for some big pharma is to slow roll and use social media and trim there holdings over time versus paying the huge bucks up front.
They cannot say anything due to legal contract with SNY. They could not tell shareholders about Afrezza penetration plan. But MNKD management continued to sell stocks (even if planned, and obviously always small amount compared to their whole portfolio) until August when they declared they will stop their selling plan to help stock price. My feeling is that management was informed about the slow launch (how can it be different ?) so they were well aware about the future PPS trend (not so ethic view if linked to their selling plan).
Now I hope that the fact they stopped in August, means they know that now Afrezza launch should change the traction ....
Don't think that shareholders are important for the company. In the past We were only an open portfolio for them and now the feeling is that shareholders are like unwanted strangers. But this is not because of MannKind or bad management. This happens always where money are.
|
|
|
|
Post by sf1981 on Oct 9, 2015 3:49:47 GMT -5
I agree Matt is not a perfectly smooth communicator and presenter. However, I think it is misguided to believe this has anything to do with the share price at this stage of the game. He actually talks pretty bullish for a CFO in his predicament. To all those who are requiring answers to a myriad of questions: keep dreaming. A CFO of a publicly listed company would be foolish to provide such specific answers. MNKD has already had a shareholder lawsuit in the past and there is a certain, though I believe small, risk of insolvency and personal liability. This is just the way this game is played. Stop wishing it would be different. Disclosure: I work in Investor Relations, but don't have anything to do with MNKD or any related stock.
|
|
|
|
Post by hammer on Oct 9, 2015 5:18:43 GMT -5
It's very frustrating, however (I feel / opinion) the current reality is that Sanofi has MNKD and us investors by the genitalia. And since there are so many unknowns who really knows what is going on. As an investor in MNKD before the final Adcom I'm frustrated as well (not to mention underwater). I would hate to be in Matt's position, however for what he's getting paid i would give it one hell of a try. For those complaining about Matt would you rather Haken take the stand? I sure wouldn't. It's impossible to know what information they have, don't and what they can't talk about. MNKD has been sued before for saying too much by investors. It's easy for expectations to get out of whack due to attachment to Afrezza, Al, Technosphere, etc for various reasons especially what potential MNKD and Afrezza have for the ever increasing diabetic population. I've been guilty of it as well. I though for sure by now we would be complaining about not being able to produce enough to meet demand. Unfortunately that isn't the case. And while i'm frustrated i added to my position today as i have been throughout the drop lowering my PPS. One question i often wonder is when Al invented the insulin pump and it was made available to patients, was it similar to this? Did insurance companies, Doctors, etc. adopt it quickly or did it take time for everyone to become educated on it, finding out about it, adopting it, etc.? I thought the important comment by Matt was that SNY is in the process of getting their insulin approved and working on plans for label improvements. If SNY was planning on backing out of the deal, per AF, why would they be trying to get their insulin approved, and planning on trials for label improvement? I guess AF is never going to get a prediction right with MNKD You hit the nail squarely on the head IMHO. Why would SNY an RHI producer invest millions of dollars on a product in which the insulin supply is dependent and potentially controlled by outside forces? Why would they conduct numerous studies to strengthen the label for a product in which their insulin is not used. SNY knows what they have in Afrezza, but they will only methodically move forward until they control the source of raw insulin. Imagine if they did ROW roll out and demand was significant. The supply is dependent upon a single AMPH plant. What if AMPH could not keep up with demand. What if AMPH were to be bought by a competitor. AMPH was always intended to be temporary. Remember the ownership change just prior to the MNKD/SNY agreement. Odd how that came about? When SNY gains approval as a secondary RHI source either by the FDA or EU filing, all hell breaks lose. They will then push the product to the wall, make the anticipated investment in MNKD. Furthermore, as they move into some markets it will be demanded of SNY that the raw insulin be manufactured in the host country. AMPH does not have that capability but SNY does.
|
|
|
|
Post by mnholdem on Oct 9, 2015 7:29:01 GMT -5
Probably not a popular sentiment, but I believe that the legal contract with SNY prevents Mnkd mgmt from saying anything. Further as historically this leads to a drop in the target company stock, it is even more strongly enforced especially during a slower launch. Forward strat plan for some big pharma is to slow roll and use social media and trim there holdings over time versus paying the huge bucks up front.
They cannot say anything due to legal contract with SNY. They could not tell shareholders about Afrezza penetration plan. But MNKD management continued to sell stocks (even if planned, and obviously always small amount compared to their whole portfolio) until August when they declared they will stop their selling plan to help stock price. My feeling is that management was informed about the slow launch (how can it be different ?) so they were well aware about the future PPS trend (not so ethic view if linked to their selling plan).
Now I hope that the fact they stopped in August, means they know that now Afrezza launch should change the traction ....
ARTICLE 8
CONFIDENTIALITY
8.1 Confidential Information. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by MannKind and Sanofi, the Parties agree that the receiving Party (the “Receiving Party”), shall keep confidential and shall not publish or otherwise disclose or use for any purpose other than as provided for in this Agreement or any other written agreement between the Parties or between the Licensors and Sanofi any confidential or proprietary information and materials, patentable or otherwise, in any form (written, oral, photographic, electronic, magnetic, or otherwise) which is disclosed or made available to it by or on behalf of the other Party (the “Disclosing Party”) including all information concerning Product and any other technical or business information of whatever nature (collectively, “Confidential Information”).
----
8.6 Publication of the Product Information. During the Term, Sanofi shall be entitled to issue scientific publications with respect to Product or its testing, in accordance with Sanofi’s internal guidelines; provided, however, that Sanofi shall adhere to academic attribution standards in any such publications; provided further, that at least thirty (30) days prior to publishing, publicly presenting and/or submitting for written or oral publication a manuscript, abstract or the like that includes Information relating to any Product that has not been previously published, Sanofi shall provide to MannKind a draft copy thereof for its review (unless Sanofi is required by Applicable Laws to publish such Information sooner, in which case Sanofi shall provide such draft copy to MannKind as much in advance of such publication as possible). Sanofi shall consider in good faith any comments provided by MannKind during such thirty (30)-day period. In addition, Sanofi shall, at MannKind’s reasonable request, remove therefrom any Confidential Information of MannKind. MannKind shall not publish or present regarding Product or its testing without Sanofi’s prior consent (except as MannKind may determine is appropriate in connection with the filing, prosecution and maintenance of the MannKind Patents or Joint Patents and/or is required to comply with Applicable Law).
www.sec.gov/Archives/edgar/data/899460/000119312514406347/d783199dex101.htm
-----
I agree with Rick on the management bashing. Think logically about this. If Sanofi were singing praises of Afrezza, while MannKind maintained strict radio silence, then investors would have something to gripe about against MannKind's management. But Sanofi has not uttered a single word about Afrezza in months, and it was not even talked at their annual meeting.
It just seems that Sanofi is enforcing this silence on Afrezza. It must be pretty difficult to defend yourself against people throwing rocks at you when your hands are tied behind your back. Bashing management under these circumstances is unwarranted, IMHO.
|
|
|
|
Post by chicagpete on Oct 9, 2015 7:35:48 GMT -5
I thought the important comment by Matt was that SNY is in the process of getting their insulin approved and working on plans for label improvements. If SNY was planning on backing out of the deal, per AF, why would they be trying to get their insulin approved, and planning on trials for label improvement? I guess AF is never going to get a prediction right with MNKD You hit the nail squarely on the head IMHO. Why would SNY an RHI producer invest millions of dollars on a product in which the insulin supply is dependent and potentially controlled by outside forces? Why would they conduct numerous studies to strengthen the label for a product in which their insulin is not used. SNY knows what they have in Afrezza, but they will only methodically move forward until they control the source of raw insulin. Imagine if they did ROW roll out and demand was significant. The supply is dependent upon a single AMPH plant. What if AMPH could not keep up with demand. What if AMPH were to be bought by a competitor. AMPH was always intended to be temporary. Remember the ownership change just prior to the MNKD/SNY agreement. Odd how that came about? When SNY gains approval as a secondary RHI source either by the FDA or EU filing, all hell breaks lose. They will then push the product to the wall, make the anticipated investment in MNKD. Furthermore, as they move into some markets it will be demanded of SNY that the raw insulin be manufactured in the host country. AMPH does not have that capability but SNY does.
I attended the conference with another member of this Board. The audio/video was f......'ed for 15 minutes as Wynnn employees tried to fix the issue. The room was sro and had twice as many people as two previous presentations that morning. I thought Matt did a fabulous job under the circumstances!!! - he was pressured by Room moderator to complete this presentation quickly- and obviously had good presentation prepared. There was much more information gathered after the conference - Matt is sharp and forthcoming - - bottom line - Hammer hits the nail on head above as well as Obamayoumama. Also - This is a highly manipulated/shorted stock - but 9M shares being returned in couple weeks. Also - Patryn's comments above are on target - I do not like where we are right now but I am content with this investment long term. We need SNY to execute and sell this product - bottom line. GWB/Joey - amazing what a good nights sleep can do. lol |
|
|
|
Post by rvc on Oct 9, 2015 8:01:33 GMT -5
You are exactly right. There seems to be some after the fact analysis that SNY and MNKD had planned this 'controlled marketing plan' all along, but Matt's negative comments clearly indicates that was never true. The marketing has been a debacle and frankly I have no faith that SNY and MNKD will suddenly get it right. The best he could come up with was there are 'rumors' about TV ads. At this point, I wouldn't be surprised to see either MNKD or SBY abandon the partnership in January.
Recently, I googled Exubera DTC marketing and found that they faced many of the exact same issues that Afrezza has, such as the lung test issues, black box warnings and insurance coverage. It seems to me that SNY learned nothing from Pfizer's previous failure. Of course, the primary differences are the size of the delivery device,less hypos, and social media(which really wasn't around in 2007). In fact, as bad as the script numbers are, where the hell would we be if twitter wasn't around.
|
|
